Budipine
Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.055.494 |
Chemical and physical data | |
Formula | C21H27N |
Molar mass | 293.454 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
While its exact mechanism of action is not well characterized, it is believed to be an NMDA receptor antagonist, but also promoting the synthesis of dopamine.
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.